Gene Targeting & Knockout Shared Resource
The Drug Metabolism & Clinical Pharmacology Shared Resource is equipped with the latest instrumentation and software necessary to support collaborative interactions between basic scientists and clinicians in the preclinical and clinical (Phase I and II) investigation of new drugs. The core offers broad, comprehensive pharmacology support in the areas of sample handling, pharmacokinetics, drug-drug interaction, pharmacodynamics, metabolite identification and human safety pharmacology.
The Drug Metabolism & Clinical Pharmacology Shared Resource offers the following services:
- Preclinical / clinical trial design and analysis
- Drug Metabolite identification: (in vivo, in vitro and ex vivo)
- Quantify drug levels in serum/plasma, tissue or cell/media
- Pharmacokinetic and pharmacodynamic studies
- Evaluation of human safety pharmacology using normal target cells from dose-limiting tissues, including hepato-, nephro- and myelo- toxicity
- Education and training
The facility is equipped with the latest HPLC and UPLC-MS instrumentation and software necessary in Phase I and II clinical trials. Available capabilities include chromatography (HPLC), spectroscopy (UV, FL, electrochemical), and electrophoresis as well as LC/MS/MS. Our LC-MS/MS facilities include a 96-well plate automated liquid-handling system and a triple quad LC-MS/MS from Waters Corporation (Micromass Quattro Premier XE) with ES and APCI ionization. The Quatro Premier UPLC/MS/MS System is an enhanced high-performance triple quadrupole mass spectrometer system with applications in protein and peptide analysis, small molecule analysis in drug metabolism and pharmacokinetic studies. The entire system is controlled by MassLynx software. Hematologic and toxicology parameters can be assayed on an Abaxis VetScan and Beckman Coulter DU800 spectrophotometer.
If you publish a manuscript including research supported by the Drug Metabolism & Clinical Pharmacology Shared Resource, the HCC recommends the following text to be placed in the acknowledgement section: "Supported in part by the Drug Metabolism & Clinical Pharmacology Shared Resource, Hollings Cancer Center, Medical University of South Carolina."